NEW YORK – UK-based gene synthesis firm Evonetix announced Monday it has closed a £23million ($29.4 million) Series B financing round.
New investor Foresite Capital led the round, joined by existing investors Draper Esprit, DCVC, the Morningside Group, Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures.